Stella Xu, Ph.D. is managing director of Quan Capital, a life science venture fund with deep expertise and broad experiences in cross-border value creation and global investments. Prior to Quan, Dr. Xu was corporate vice president/site head of Roche R&D Center China and a core member of the global management team of Roche’s Immunology, Inflammation & Infectious Diseases Division. From 2012 to 2017, she led the fully integrated team of approximately 200 scientists to deliver an innovative pipeline from discovery to global clinical development. She also had extensive global business development experience with Roche Partnering. Dr. Xu joined Roche from McKinsey US and worked in biotech R&D earlier in her career. Dr. Xu currently serves on the boards of Walking Fish Therapeutics, Zidan Medical, HBM Healthcare Investments AG and Therorna Inc. She was also previously a board member of ARMO BioSciences (ARMO), NextCure (NXTC), Centrexion Therapeutics and Tempest Therapeutics. Dr. Xu received her Ph.D. in immunology from Northwestern University and B.S. in biophysics from Peking University.